Cliff Asness's ENTA Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 256,870 shares of Enanta Pharmaceuticals, Inc. (ENTA) worth $3.75 M, representing 0.00% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 49 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in ENTA, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2025, adding 311,010 shares. Largest reduction occurred in Q3 2025, reducing 169,265 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Enanta Pharmaceuticals (ENTA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Enanta Pharmaceuticals (ENTA) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -56,287 | Reduce 17.97% | 256,870 | $14.58 |
| Q1 2026 | +78,322 | Add 33.35% | 313,157 | $12.63 |
| Q4 2025 | +7,990 | Add 3.52% | 234,835 | $15.77 |
| Q3 2025 | -169,265 | Reduce 42.73% | 226,845 | $11.97 |
| Q2 2025 | +39,001 | Add 10.92% | 396,110 | $7.56 |
| Q1 2025 | +311,010 | Add 674.66% | 357,109 | $5.52 |
| Q4 2024 | +8,240 | Add 21.76% | 46,099 | $5.75 |
| Q3 2024 | -22,146 | Reduce 36.91% | 37,859 | $10.36 |
| Q2 2024 | -49,701 | Reduce 45.30% | 60,005 | $12.97 |
| Q1 2024 | -93,558 | Reduce 46.03% | 109,706 | $17.46 |
| Q4 2023 | +65,488 | Add 47.53% | 203,264 | $9.41 |
| Q3 2023 | +118,320 | Add 608.14% | 137,776 | $11.17 |
| Q2 2023 | +9,490 | Add 95.22% | 19,456 | $21.40 |
| Q1 2023 | -7,261 | Reduce 42.15% | 9,966 | $40.44 |
| Q4 2022 | +7,508 | Add 77.25% | 17,227 | $46.52 |
| Q3 2022 | +2,229 | Add 29.76% | 9,719 | $51.86 |
| Q2 2022 | -503 | Reduce 6.29% | 7,490 | $47.26 |
| Q1 2022 | -6,120 | Reduce 43.36% | 7,993 | $71.19 |
| Q4 2021 | +7,554 | Add 115.17% | 14,113 | $74.75 |
| Q3 2021 | -1,407 | Reduce 17.66% | 6,559 | $56.87 |
| Q2 2021 | -208 | Reduce 2.54% | 7,966 | $44.06 |
| Q1 2021 | -27,623 | Reduce 77.17% | 8,174 | $49.30 |
| Q4 2020 | -8,400 | Reduce 19.01% | 35,797 | $42.10 |
| Q3 2020 | -18,029 | Reduce 28.97% | 44,197 | $45.77 |
| Q2 2020 | -15,729 | Reduce 20.18% | 62,226 | $50.20 |
| Q1 2020 | -37,276 | Reduce 32.35% | 77,955 | $51.43 |
| Q4 2019 | -22,604 | Reduce 16.40% | 115,231 | $61.78 |
| Q3 2019 | +13,732 | Add 11.07% | 137,835 | $60.08 |
| Q2 2019 | -18,461 | Reduce 12.95% | 124,103 | $84.38 |
| Q1 2019 | -45,235 | Reduce 24.09% | 142,564 | $95.52 |
| Q4 2018 | +58,463 | Add 45.20% | 187,799 | $70.83 |
| Q3 2018 | +8,936 | Add 7.42% | 129,336 | $85.46 |
| Q2 2018 | -13,009 | Reduce 9.75% | 120,400 | $115.90 |
| Q1 2018 | -21,773 | Reduce 14.03% | 133,409 | $80.92 |
| Q4 2017 | -2,811 | Reduce 1.78% | 155,182 | $58.68 |
| Q3 2017 | +20,270 | Add 14.72% | 157,993 | $46.80 |
| Q2 2017 | +13,669 | Add 11.02% | 137,723 | $35.98 |
| Q1 2017 | +10,260 | Add 9.02% | 124,054 | $30.79 |
| Q4 2016 | +9,977 | Add 9.61% | 113,794 | $33.50 |
| Q3 2016 | +57,559 | Add 124.43% | 103,817 | $26.61 |
| Q2 2016 | +2,822 | Add 6.50% | 46,258 | $22.05 |
| Q1 2016 | -7,567 | Reduce 14.84% | 43,436 | $29.38 |
| Q4 2015 | -3,471 | Reduce 6.37% | 51,003 | $33.02 |
| Q3 2015 | +5,226 | Add 10.61% | 54,474 | $36.15 |
| Q2 2015 | +7,786 | Add 18.78% | 49,248 | $45.00 |
| Q1 2015 | -17,518 | Reduce 29.70% | 41,462 | $30.63 |
| Q4 2014 | -220 | Reduce 0.37% | 58,980 | $50.85 |
| Q3 2014 | +38,300 | Add 183.25% | 59,200 | $39.58 |
| Q2 2014 | +20,900 | New Buy | 20,900 | $43.06 |
Cliff Asness's Enanta Pharmaceuticals Investment FAQs
Cliff Asness first purchased Enanta Pharmaceuticals, Inc. (ENTA) in Q2 2014, acquiring 20,900 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Enanta Pharmaceuticals, Inc. (ENTA) for 49 quarters since Q2 2014.
Cliff Asness's largest addition to Enanta Pharmaceuticals, Inc. (ENTA) was in Q1 2025, adding 357,109 shares worth $1.97 M.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 256,870 shares of Enanta Pharmaceuticals, Inc. (ENTA), valued at approximately $3.75 M.
As of the Q2 2026 filing, Enanta Pharmaceuticals, Inc. (ENTA) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Enanta Pharmaceuticals, Inc. (ENTA) was 396,110 shares, as reported at the end of Q2 2025.